J B Chemicals and Pharmaceuticals Limited has announced another significant change in its senior management structure, disclosing the resignation of Ms. Sushree Mishra as General Manager-Corporate Strategy, Communication and In-licensing, effective March 13, 2026. This marks the fourth senior executive departure within the same month, following the earlier resignations of three other key executives.

Latest Senior Management Departure

Ms. Sushree Mishra formally submitted her resignation on February 9, 2026, requesting her last working day to be March 15, 2026, subject to organizational requirements. The company disclosed her cessation from the position effective from closing of business hours on March 13, 2026.

Previous Senior Management Departures

This latest departure follows the resignation of three other senior executives earlier in March 2026, creating a significant transition period for the pharmaceutical company's leadership structure.

Resignation Details and Transition

In her resignation letter addressed to the management, Ms. Sushree Mishra expressed gratitude for the opportunities and support provided during her tenure at JB Pharma, describing it as a valuable and enriching experience. She committed to ensuring a smooth transition of her responsibilities during the notice period and wished the organization continued success.

Regulatory Compliance and Disclosure

The disclosure was made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication referenced SEBI Master Circulars bearing reference numbers SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and September 9, 2015.

Sandeep Phadnis, Vice President – Secretarial & Company Secretary, signed the formal communication to BSE Limited on March 13, 2026, requesting the exchange to take the resignation on record. The company provided a copy of the resignation letter as supporting documentation for the regulatory filing.

Company Operations

J.B. Chemicals & Pharmaceuticals Limited continues its pharmaceutical operations while managing this significant transition in senior leadership positions. The company maintains its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai, Maharashtra, operating under the tagline "Good People for Good Health."

J B Chemicals and Pharmaceuticals Limited has announced the allotment of 31,160 equity shares under its Employee Stock Option Scheme (ESOP), marking another milestone in the company's employee incentive program. The pharmaceutical company disclosed this development to BSE Limited on February 19, 2026, in compliance with regulatory requirements.

ESOP Allotment Details

The Compensation Committee of the Board of Directors approved the allotment of 31,160 fully paid-up equity shares of Re. 1 each to one ESOP holder. The shares were allotted following the exercise of stock options granted under the JBCPL Employee Stock Option Scheme, 2021.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued, subscribed and paid-up capital. The share capital structure has been updated to reflect the new equity base following the ESOP exercise.

Regulatory Compliance

The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015. The communication was sent to BSE Limited, where the company's shares are listed under scrip code 506943 and stock symbol JBCHEPHARM. The disclosure also references the SEBI Master Circular bearing reference number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Information

J.B. Chemicals & Pharmaceuticals Limited operates with its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai, Maharashtra. The company, incorporated with CIN L24390GJ1976PLC173077, continues to execute its employee stock option schemes as part of its human resource strategy. The allotment was communicated by Sandeep Phadnis, Vice President – Secretarial & Company Secretary, ensuring proper regulatory compliance and transparency.